S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
S&P 500   4,109.31 (+1.44%)
DOW   33,274.15 (+1.26%)
QQQ   320.93 (+1.66%)
AAPL   164.90 (+1.56%)
MSFT   288.30 (+1.50%)
META   211.94 (+1.97%)
GOOGL   103.73 (+2.81%)
AMZN   103.29 (+1.26%)
TSLA   207.46 (+6.24%)
NVDA   277.77 (+1.44%)
NIO   10.51 (+0.48%)
BABA   102.18 (-1.16%)
AMD   98.01 (+0.13%)
T   19.25 (+0.89%)
F   12.60 (+2.52%)
MU   60.34 (-4.36%)
CGC   1.75 (-0.57%)
GE   95.60 (+1.65%)
DIS   100.13 (+2.07%)
AMC   5.01 (+0.80%)
PFE   40.80 (+1.04%)
PYPL   75.94 (+2.08%)
NFLX   345.48 (+2.08%)
NASDAQ:XNCR

Xencor - XNCR Stock Forecast, Price & News

$27.89
+0.49 (+1.79%)
(As of 03/31/2023 05:17 PM ET)
Add
Compare
Today's Range
$27.50
$28.24
50-Day Range
$26.86
$36.95
52-Week Range
$19.35
$38.20
Volume
342,173 shs
Average Volume
390,221 shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.13

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.09 Rating Score
Upside/​Downside
66.4% Upside
$46.13 Price Target
Short Interest
Bearish
8.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
1.02mentions of Xencor in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$739,628 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.80) to ($2.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

310th out of 1,009 stocks

Pharmaceutical Preparations Industry

136th out of 494 stocks


XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Xencor Full Year 2022 Earnings: EPS Beats Expectations
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Why Shares of Zencor Rose This Week
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
Xencor Earnings Preview
Xencor Inc
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Company Calendar

Last Earnings
2/23/2023
Today
3/31/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.13
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+65.4%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Net Income
$-55,180,000.00
Pretax Margin
-33.12%

Debt

Sales & Book Value

Annual Sales
$164.58 million
Book Value
$12.14 per share

Miscellaneous

Free Float
57,491,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
0.82

Key Executives

  • Bassil I. DahiyatBassil I. Dahiyat
    President, Chief Executive Officer & Director
  • John J. Kuch
    Chief Financial Officer & Senior Vice President
  • John R. Desjarlais
    Chief Scientific Officer & Senior VP-Research
  • Allen YangAllen Yang
    Chief Medical Officer & Senior Vice President
  • Celia Eckert
    Secretary, Senior Vice President & General Counsel













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

11 brokers have issued 1 year price targets for Xencor's shares. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they expect the company's share price to reach $46.13 in the next year. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2023?

Xencor's stock was trading at $26.04 at the start of the year. Since then, XNCR stock has increased by 7.1% and is now trading at $27.89.
View the best growth stocks for 2023 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Thursday, February, 23rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.63. The biopharmaceutical company earned $21.61 million during the quarter, compared to analyst estimates of $19.24 million. Xencor had a negative trailing twelve-month return on equity of 7.47% and a negative net margin of 33.53%. The business's revenue for the quarter was down 86.0% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include T. Rowe Price Investment Management Inc. (6.23%), Price T Rowe Associates Inc. MD (5.37%), Dimensional Fund Advisors LP (2.11%), Geode Capital Management LLC (1.89%), Norges Bank (0.90%) and Morgan Stanley (0.81%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch and John S Stafford III.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $27.89.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $164.58 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 3/31/2023 by MarketBeat.com Staff